• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.

作者信息

Erba Paola A, Maecke Helmut, Mikolajczak Renata, Decristoforo Clemens, Zaletel Katja, Maina-Nock Theodosia, Peitl Petra Kolenc, Garnuszek Piotr, Froberg Alida, Goebel Georg, de Jong Marion, Jabrocka-Hybel Agata, Konijnenberg Mark, Virgolini Irena, Nock Berthold, Lenda-Tracz Wioletta, Pawlak Dariusz, Rangger Christine, Trofimiuk-Müldner Małgorzata, Sowa-Staszczak Anna, Tomaszuk Monika, von Guggenberg Elisabeth, Scarpa Lorenza, Hubalewska-Dydejczyk Alicja

出版信息

Pol Arch Intern Med. 2018 Dec 21;128(12):791-795. doi: 10.20452/pamw.4387. Epub 2018 Dec 5.

DOI:10.20452/pamw.4387
PMID:30516761
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6347971/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40f1/6347971/a6cec50531e8/emss-81347-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40f1/6347971/a6cec50531e8/emss-81347-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40f1/6347971/a6cec50531e8/emss-81347-f001.jpg

相似文献

1
A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.一种用于进行性或转移性甲状腺髓样癌患者个性化诊断和治疗的新型CCK2/胃泌素受体定位放射性标记肽探针：一项多中心I期GRAN-T-MTC研究。
Pol Arch Intern Med. 2018 Dec 21;128(12):791-795. doi: 10.20452/pamw.4387. Epub 2018 Dec 5.
2
[In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial.在 CP04 作为一种新型胆囊收缩素-2 受体配体，在进展性或转移性甲状腺髓样癌患者中具有治疗潜力：GRAN-T-MTC Ⅰ期临床试验的最终结果。
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):892-907. doi: 10.1007/s00259-022-05992-6. Epub 2022 Nov 5.
3
Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.利用循环肿瘤标志物进行甲状腺髓样癌的诊断和管理。
Pathol Res Pract. 2022 Jan;229:153694. doi: 10.1016/j.prp.2021.153694. Epub 2021 Nov 24.
4
Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.甲状腺髓样癌的流行病学与临床表现
Recent Results Cancer Res. 2015;204:61-90. doi: 10.1007/978-3-319-22542-5_3.
5
The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.转移性甲状腺髓样癌的困境：何时开始全身治疗。
Tumori. 2019 Dec;105(6):NP28-NP31. doi: 10.1177/0300891619829571. Epub 2019 Feb 19.
6
[Medullary thyroid carcinoma].甲状腺髓样癌
Internist (Berl). 2015 Sep;56(9):1019-31. doi: 10.1007/s00108-014-3638-z.
7
Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.结构倍增时间可预测接受分子靶向治疗的快速进展性转移性甲状腺髓样癌患者的总体生存。
Thyroid. 2020 Aug;30(8):1112-1119. doi: 10.1089/thy.2019.0579. Epub 2020 Apr 20.
8
Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues.甲状腺髓样癌——使用68Ga标记的胃泌素和生长抑素类似物的PET/CT成像
Endokrynol Pol. 2016;67(1):68-71. doi: 10.5603/EP.2016.0010.
9
Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry.甲状腺髓样癌监测研究：病例系列登记
Thyroid. 2020 Oct;30(10):1397-1398. doi: 10.1089/thy.2019.0591. Epub 2020 Jul 9.
10
[Progression of diagnosis and treatment of medullary thyroid carcinoma].[甲状腺髓样癌的诊断与治疗进展]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Apr 7;54(4):306-310. doi: 10.3760/cma.j.issn.1673-0860.2019.04.015.

引用本文的文献

1
Medullary Thyroid Cancer: Updates and Challenges.甲状腺髓样癌：更新与挑战。
Endocr Rev. 2023 Sep 15;44(5):934-946. doi: 10.1210/endrev/bnad013.
2
[In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial.在 CP04 作为一种新型胆囊收缩素-2 受体配体，在进展性或转移性甲状腺髓样癌患者中具有治疗潜力：GRAN-T-MTC Ⅰ期临床试验的最终结果。
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):892-907. doi: 10.1007/s00259-022-05992-6. Epub 2022 Nov 5.
3
Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?

本文引用的文献

1
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients.甲状腺髓样癌患者进行¹¹¹In - CP04的I期临床试验的监管批准所需的临床前药代动力学、生物分布、辐射剂量测定和毒性研究。
Eur J Pharm Sci. 2016 Aug 25;91:236-42. doi: 10.1016/j.ejps.2016.05.011. Epub 2016 May 14.
2
From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.从临床前开发到临床应用：用于用铟-111对小胃泌素类似物CP04进行放射性标记的试剂盒配方，用于首次人体临床试验。
Eur J Pharm Sci. 2016 Mar 31;85:1-9. doi: 10.1016/j.ejps.2016.01.023. Epub 2016 Jan 27.
3
甲状腺髓样癌诊断与管理的最新进展：近年来有哪些变化？
Cancers (Basel). 2022 Jul 27;14(15):3643. doi: 10.3390/cancers14153643.
4
Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.分子影像学表型用于选择和监测神经内分泌肿瘤的放射性配体治疗。
Cancer Imaging. 2022 Jun 3;22(1):25. doi: 10.1186/s40644-022-00465-3.
5
Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCKR Cancer Theranostic Agents: A Preclinical Study.标记有三价放射性金属的非肽类Z360类似物作为抗CCKR癌症诊疗剂的临床前研究。
Pharmaceutics. 2022 Mar 18;14(3):666. doi: 10.3390/pharmaceutics14030666.
6
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.胆囊收缩素-2受体靶向放射性药物的临床前开发与临床转化进展
Cancers (Basel). 2021 Nov 18;13(22):5776. doi: 10.3390/cancers13225776.
7
Radiopharmaceutical Formulation and Preclinical Testing of Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.用于首个探索性临床试验监管批准的镓标记DOTA-MGS5的放射性药物制剂及临床前测试
Pharmaceuticals (Basel). 2021 Jun 16;14(6):575. doi: 10.3390/ph14060575.
8
Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy.甲状腺髓样癌治疗进展：聚焦于肽受体放射性核素治疗
J Clin Med. 2020 Oct 29;9(11):3507. doi: 10.3390/jcm9113507.
9
Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.新型 CCK2R 靶向肽类似物的体外和体内初步评价，该类似物用镥-177 标记。
Molecules. 2020 Oct 8;25(19):4585. doi: 10.3390/molecules25194585.
10
Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.胆囊收缩素-2 受体放射性肽靶向：现状与未来方向。
Curr Med Chem. 2020;27(41):7112-7132. doi: 10.2174/0929867327666200625143035.
Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.氨基酸间隔臂的立体化学决定了用于靶向CCK2/胃泌素受体的（111）铟-DOTA-胃泌素类似物的药代动力学。
Bioconjug Chem. 2015 Jun 17;26(6):1113-9. doi: 10.1021/acs.bioconjchem.5b00187. Epub 2015 May 20.
4
Procalcitonin for detecting medullary thyroid carcinoma: a systematic review.降钙素原用于检测甲状腺髓样癌：一项系统评价
Endocr Relat Cancer. 2015 Jun;22(3):R157-64. doi: 10.1530/ERC-15-0156. Epub 2015 May 1.
5
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.美国甲状腺协会修订的甲状腺髓样癌管理指南。
Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335.
6
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.凡德他尼治疗晚期甲状腺髓样癌：不良事件管理策略综述
Adv Ther. 2013 Nov;30(11):945-66. doi: 10.1007/s12325-013-0069-5. Epub 2013 Nov 19.
7
Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.放射性标记的 DOTA 衍生环最小胃泌素类似物用于靶向表达胆囊收缩素受体的恶性肿瘤的临床前评估。
Mol Imaging Biol. 2012 Jun;14(3):366-75. doi: 10.1007/s11307-011-0506-2.
8
Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.CCK2 受体靶向肽的生物稳定性和代谢比较，COST BM0607 合作项目。
Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1426-35. doi: 10.1007/s00259-011-1818-9. Epub 2011 Apr 29.
9
Medullary thyroid carcinoma: targeted therapies and future directions.甲状腺髓样癌：靶向治疗及未来方向。
J Oncol. 2009;2009:183031. doi: 10.1155/2009/183031. Epub 2009 Dec 24.
10
Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer.甲状腺髓样癌预后的临床不可预测因素。
Endocr Relat Cancer. 2007 Dec;14(4):1099-105. doi: 10.1677/ERC-07-0128.